Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cimetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.69 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ATP4A | P20648 | 1/20 | 0.69 |
| ▸ | APEX1 | P27695 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ATP4B | P51164 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.69 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cimetidine SCHEMBL10855569 | 1.00 | SLC47A1 (0.69) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL1163516 | 1.00 | SLC47A1 (0.69) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL10859058 | 1.00 | SLC47A1 (0.69) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL10855575 | 1.00 | SLC47A1 (0.69) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL2873984 | 1.00 | SLC47A1 (0.69) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL2873981 | 1.00 | SLC47A1 (0.69) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL7110586 | 0.99 | SLC47A1 (0.67) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL9403120 | 0.99 | SLC47A1 (0.67) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL8912417 | 0.99 | SLC47A1 (0.67) | SLC47A1HRH2MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL11156753 | 0.99 | SLC47A1 (0.67) | SLC47A1HRH2MEN1SLC22A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 49308 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121774464-B | Intestinal canal stenosis detection device based on bicolor indication and preparation method thereof | BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122037926-A | Luminescent material, preparation method thereof and photoelectric device | 甬江实验室 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| WO-2026088112-A1 | COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS | NOVARTIS AG (CH) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4114975-B1 | FASCIN-2 (FSCN2) VARIANT AND USE THEREOF | REGENERON PHARMA (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-0040489-A1 | Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine | FISONS plc (GB) | 1981-11-25 | — | — | EP | claimed |
| US-4293562-A | Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine | RITTER ARNOLD | 1981-10-06 | — | — | US | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| US-4279886-A | Test for pancreatic exocrine function | UNIVERSITY PATENTS, INC. (US) | 1981-07-21 | — | — | US | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |
| EP-0020757-A1 | TEST FOR PANCREATIC EXOCRINE FUNCTION | UNIVERSITY PATENTS, INC. (US) | 1981-01-07 | — | — | EP | claimed |
| US-4230717-A | METIAMIDE OR CEMETIDINE | LOVELACE ALAN M ADMINISTRATOR | 1980-10-28 | — | — | US | claimed |
| US-4220653-A | ANTISECRETORY | VIVINO A EARL | 1980-09-02 | — | — | US | claimed |
| WO-1980001415-A1 | TEST FOR PANCREATIC EXOCRINE FUNCTION | ALLEN R | 1980-07-10 | — | — | WO | claimed |
| US-4171353-A | Immunization of animals using choline esters as an immunological adjuvant | RYAN WAYNE L | 1979-10-16 | — | — | US | claimed |